Janux Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Janux Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue10.598.088.613.640.00
Cost of Revenue2.0654.9253.4426.243.04
Gross Profit8.538.08-44.833.64-3.04
Operating Expenses
Research & Development68.3954.9253.4426.240.00
Selling, General & Administrative41.0526.1422.2610.331.80
Operating Expenses109.4481.0622.2636.571.80
Operating Income-98.85-72.98-67.09-32.93-4.84
Other Income/Expense
Interest Income29.8514.694.030.260.00
Interest Expense0.000.000.000.00-0.21
Other Income/Expense29.85-2.80-0.20-0.300.00
Income
Income Before Tax-68.99-58.29-63.06-32.67-6.78
Income Tax Expense0.00-2.83-3.75-2.170.00
Net Income-68.99-58.29-63.06-32.67-6.78
Net Income - Continuous Operations-68.99-58.29-63.06-32.670.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-96.79-59.17-66.25-32.73-4.83
EBIT-98.85-61.12-67.09-32.67-4.84
Depreciation & Amortization2.061.960.840.110.01
Earnings Per Share
Basic EPS-1.00-1.00-2.00-1.00-7.00
Diluted EPS-1.00-1.00-2.00-1.00-7.00
Basic Shares Outstanding53.7544.0241.4723.530.92
Diluted Shares Outstanding53.7544.0241.4723.530.92